|
2023 Journal Article Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myelomaTeh, Benjamin W., Reynolds, Gemma, Slavin, Monica A., Cooley, Louise, Roberts, Matthew, Liu, Eunice, Thursky, Karin, Talaulikar, Dipti, Mollee, Peter, Szabo, Ferenc, Ward, Chris, Chan, Henry, Prince, H. Miles, Harrison, Simon J. and the Medical and Scientific Advisory Group, Myeloma Australia and National Centrefor Infections in Cancer (2023). Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma. Internal Medicine Journal, 53 (8), 1469-1477. doi: 10.1111/imj.16100 |
|
2023 Journal Article Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiographyFerkh, Aaisha, Tjahjadi, Catherina, Stefani, Luke, Geenty, Paul, Byth, Karen, De Silva, Kasun, Boyd, Anita C., Richards, David, Mollee, Peter, Korczyk, Dariusz, Taylor, Mark S., Kwok, Fiona, Kizana, Eddy, Ng, Arnold C. T. and Thomas, Liza (2023). Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography. Frontiers in Cardiovascular Medicine, 10 1183485. doi: 10.3389/fcvm.2023.1183485 |
|
2023 Journal Article The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma AustraliaSim, Shirlene, Kalff, Anna, Tuch, Gina, Mollee, Peter, Ho, Joy, Harrison, Simon, Gibbs, Simon, Prince, H. Miles, Spencer, Andrew, Joshua, Douglas, Lee, Cindy, Ling, Silvia, Murphy, Nick, Szabo, Ferenc, Szer, Jeff, Weber, Nicholas, Ward, Christopher, Talaulikar, Dipti, Zannettino, Andrew and Quach, Hang (2023). The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma Australia. Internal Medicine Journal, 53 (5), 819-824. doi: 10.1111/imj.16049 |
|
2023 Journal Article Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemiaBurgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631 |
|
2023 Journal Article Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic reviewNicol, Jennifer L., Chong, Jamie E., McQuilten, Zoe K., Mollee, Peter, Hill, Michelle M. and Skinner, Tina L. (2023). Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia, 23 (2), 86-96. doi: 10.1016/j.clml.2022.10.003 |
|
2023 Journal Article Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphomaMistry, Vijay, Scott, Justin R., Wang, Tzu-Yang, Mollee, Peter, Miles, Kenneth A., Law, W. Phillip and Hapgood, Greg (2023). Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma. Cancer Imaging, 23 (1) 11, 1-11. doi: 10.1186/s40644-023-00520-7 |
|
2023 Journal Article The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand PopulationTan, Joanne L. C., Wellard, Cameron, Moore, Elizabeth M., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Harrison, Simon James, McDonald, Emma‐Jane, Ho, P. Joy, Prince, H. Miles, Augustson, Bradley M., Campbell, Philip, McQuilten, Zoe K., Wood, Erica M., Spencer, Andrew and Myeloma and Related Diseases Registry Investigators (2023). The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. British Journal of Haematology, 200 (2), e17-e21. doi: 10.1111/bjh.18536 |
|
2022 Journal Article Current approaches to the diagnosis and management of amyloidosisTaylor, Mark S., Sidiqi, Hasib, Hare, James, Kwok, Fiona, Choi, Bo, Lee, Darren, Baumwol, Jay, Carroll, Antonia S., Vucic, Steve, Neely, Pat, Korczyk, Dariusz, Thomas, Liza, Mollee, Peter, Stewart, Graeme J. and Gibbs, Simon D. J. (2022). Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal, 52 (12), 2046-2067. doi: 10.1111/imj.15974 |
|
2022 Journal Article Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyLandgren, Ola, Weisel, Katja, Rosinol, Laura, Touzeau, Cyrille, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Shu, Natalie, Hu, Xuguang, Li, Chuang and Usmani, Saad Z. (2022). Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. British Journal of Haematology, 198 (6), 988-993. doi: 10.1111/bjh.18233 |
|
2022 Journal Article Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)McQuilten, Zoe, Wellard, Cameron, Moore, Elizabeth, Augustson, Bradley, Bergin, Krystal, Blacklock, Hilary, Harrison, Simon, Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rosengarten, Brian, Walker, Patricia, Wood, Erica, Spencer, Andrew and Australian and New Zealand Myeloma and Related Diseases Registry (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British Journal of Haematology, 198 (5), 830-837. doi: 10.1111/bjh.18324 |
|
2022 Journal Article Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA studySanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon, Mollee, Peter, Venner, Christopher, Lu, Jin, Schönland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, María Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, Tran, Nam Phuong, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica ... Wechalekar, Ashutosh D. (2022). Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study. American Journal of Hematology, 97 (6), 719-730. doi: 10.1002/ajh.26536 |
|
2022 Journal Article An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trialNicol, Jennifer L., Woodrow, Carmel, Cunningham, Brent J., Mollee, Peter, Weber, Nicholas, Smith, Michelle D., Nicol, Andrew J., Gordon, Louisa G., Hill, Michelle M. and Skinner, Tina L. (2022). An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial. Current Oncology, 29 (2), 901-923. doi: 10.3390/curroncol29020077 |
|
2022 Journal Article Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Joy Ho, P., Mollee, Peter, D’Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J., Reynolds, John, Kennedy, Nola, Quach, Hang and Spencer, Andrew (2022). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica, 107 (1), 321-325. doi: 10.3324/haematol.2021.278655 |
|
2022 Journal Article Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelinesSanchorawala, Vaishali, Boccadoro, Mario, Gertz, Morie, Hegenbart, Ute, Kastritis, Efstathios, Landau, Heather, Mollee, Peter, Wechalekar, Ashutosh and Palladini, Giovanni (2022). Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid, 29 (1), 1-7. doi: 10.1080/13506129.2021.2002841 |
|
2021 Journal Article The role of a routine bone marrow biopsy in autoimmune hemolytic anemia for the detection of an underlying lymphoproliferative disorderCampbell, Ashlea, Podbury, Bridget, Yue, Mimi, Mollee, Peter, Bird, Robert and Hapgood, Greg (2021). The role of a routine bone marrow biopsy in autoimmune hemolytic anemia for the detection of an underlying lymphoproliferative disorder. HemaSphere, 6 (1), e674-e674. doi: 10.1097/hs9.0000000000000674 |
|
2021 Journal Article Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertionsJones, M., Okano, S., Looke, D., Kennedy, G., Pavilion, G., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Mollee, P. (2021). Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions. Journal of Hospital Infection, 118, 70-76. doi: 10.1016/j.jhin.2021.10.008 |
|
2021 Journal Article Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma AllianceBoyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Gullapalli, Veena, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles, Johnston, Anna M., Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Jabbour, Andrew, Strasser, Simone, Chadban, Steven J., Brown, Christina, Mollee, Peter and Hapgood, Greg (2021). Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma Alliance. HemaSphere, 5 (11) e648, 1-8. doi: 10.1097/hs9.0000000000000648 |
|
2021 Journal Article Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaCreeper, Katherine, Augustson, Bradley, Kusel, Kieran, Fulham, Michael J., Ho, Joy, Quach, Hang, Mollee, Peter, Weber, Nicholas, Talaulikar, Dipti, Johnston, Anna, Murphy, Nick, Joshua, Douglas, Ward, Christopher, Ling, Silvia, Gibson, John, Szer, Jeff, Harrison, Simon, Zannettino, Andrew, Jaksic, Wilfrid, Lee, Cindy, Spencer, Andrew, Kalff, Anna, Szabo, Ferenc, Romeril, Ken, Chan, Henry, Gibbs, Simon, Horvath, Noemi and Prince, H. Miles (2021). Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 51 (10), 1707-1712. doi: 10.1111/imj.15457 |
|
2021 Journal Article Daratumumab-based treatment for immunoglobulin light-chain amyloidosisKastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon, Mollee, Peter, Venner, Christopher P., Lu, Jin, Schönland, Stefan, Gatt, Moshe E., Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Huart, Antoine, Dimopoulos, Meletios A., Bhutani, Divaya, Waxman, Adam J., Goodman, Stacey A., Zonder, Jeffrey A. ... Comenzo, Raymond L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385 (1), 46-58. doi: 10.1056/NEJMoa2028631 |
|
2021 Journal Article Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based inductionBoyle, Stephen, Wellard, Cameron, Moore, Elizabeth M., Blacklock, Hilary, Harrison, Simon J., Ho, Phoebe Joy, Hocking, Jay, McQuilten, Zoe K., Quach, Hang, Spearing, Ruth, Wood, Erica M., Spencer, Andrew and Mollee, Peter (2021). Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. European Journal of Haematology, 107 (4) ejh.13677, 497-499. doi: 10.1111/ejh.13677 |
